BioFluidica, a US-based privately held biotechnology company, announced on Friday that it planning to commercialise the LiquidScan Automated Liquid Biopsy System, a high throughput rare biomarker (circulating tumour cells, exosomes, and cell-free DNA) enrichment solution.
The company has designed and developed an automation-ready liquid biopsy instrument compatible with Hamilton Robotics Microlab STAR series liquid handlers. The commercial version of the LiquidScan system is produced under present Good Manufacturing Practices and includes complete documentation to facilitate clinical application development and clinical trials under EUA and FDA guidelines.
BioFluidica is offering a limited number of systems to certain Core facilities in North America through Early Technology Access Program from fourth quarter of 2021.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval